1 - 10 of 51 articles
—In the Letter From Australia entitled "The Australian Health Care System: Are the Incentives Down Under Right Side Up?" published in the December 25, 1996, issue of The Journal (1996;276:1944-1950), the author for reference 20 is incorrect. The correct author is the Australian Health...
—In the Original Contribution entitled "Chlamydia pneumoniae as a New Source of Infectious Outbreaks in Nursing Homes," published in the April 16, 1997, issue of The Journal (1997;277:1214-1218), 2 incorrect P values appeared. On page 1216, in the second paragraph of the third column...
—To provide an evidence-based practice guideline on the pharmacological management of alcohol withdrawal.
—English-language articles published before July 1, 1995, identified through MEDLINE search on...
The call came at 5:30 AM on Sunday, January 19. The unthinkable had happened: our humanitarian mission in Rwanda had been attacked. Three volunteers were shot and killed, and our project director was severely injured.1
The mission, in place just 3 weeks, was providing medical...
Abstract To the Editor. —We were intrigued by the findings of Dr Snowdon and colleagues1 in the prospective study of elderly nuns that fewer neuropathologic lesions of Alzheimer disease (AD), especially neurofibrillary tangles (NFTs), apparently resulted in dementia in individuals with...
—Given the similarities between Alzheimer disease and dementia pugilistica, we evaluated the relationship between apolipoprotein E (APOE) genotype and chronic traumatic brain injury (CTBI) in boxers to determine whether there is a genetic susceptibility to...
SWITCHING DRUGS from prescription to over-the-counter (OTC) status is proceeding at an ever-increasing pace. In the 10years from 1984 to 1994,9drugs were switched from prescription to OTC status—an average of about 1 a year. But in 1995 alone, 7 agents were moved to OTC status, and last...
—Monotherapy with dopamine agonists may be useful in early Parkinson disease.
—To evaluate dose-response relationships for tolerability, safety, and efficacy of the synthetic dopamine agonist pramipexole....
Read and print from thousands of top scholarly journals.
Continue with Facebook
Sign up with Google
Log in with Microsoft
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.